



# Cigna Medical Coverage Policy

Subject **Somatosensory Evoked Potentials**

Effective Date ..... **2/15/2013**  
Next Review Date ..... **9/15/2013**  
Coverage Policy Number ..... **0122**

## Table of Contents

Coverage Policy ..... 1  
 General Background ..... 2  
 Coding/Billing Information ..... 6  
 References ..... 9

## Hyperlink to Related Coverage Policies

[Nerve Conduction Velocity Studies and Electromyography](#)  
[Quantitative Sensory Testing \(QST\)](#)

### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna companies including plans formerly administered by Great-West Healthcare, which is now a part of Cigna. Coverage Policies are intended to provide guidance in interpreting certain **standard** Cigna benefit plans. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document **always supercedes** the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Proprietary information of Cigna. Copyright ©2013 Cigna

## Coverage Policy

Cigna covers somatosensory evoked potentials (SSEPs) as medically necessary when prior diagnostic testing has failed to confirm a diagnosis for **ANY** of the following:

- coma
- myoclonus
- multiple sclerosis and other demyelinating diseases (e.g., adrenoleukodystrophy, adrenomyeloneuropathy, metachromatic leukodystrophy, and Pelizaeus-Merzbacher disease)
- spinocerebellar degeneration
- spinal cord trauma
- subacute combined degeneration of the spinal cord (e.g., Lichtheim disease)
- degenerative nontraumatic spinal cord lesions (e.g., cervical spondylotic myelopathy)
- syringomyelia
- hereditary spastic paraplegia

Cigna does not cover SSEPs for **ANY** other indication, including the evaluation of disorders of the lumbosacral roots, such as radiculopathies, thoracic root disorders, or cervical root disorders because it is considered experimental, investigational or unproven for these indications.

Cigna covers intraoperative monitoring\* (IOM) of somatosensory evoked potentials (SSEPs) as medically necessary when **ALL** of the following conditions are met:

- There is significant risk of nerve or spinal cord injury during a surgical procedure, such as the following (this list may not be all inclusive):
  - aortic and thoracic aneurysm repair
  - aortic cross-clamping
  - arteriovenous malformation of the of the spinal cord
  - brachial plexus surgery/brachial plexus exploration after injury to the brachial plexus
  - cerebral vascular surgery (e.g., carotid endarterectomy, cerebral aneurysm, hypothermic coronary bypass procedures)
  - clipping of intracranial aneurysms
  - cortical localization
  - interventional neuroradiology
  - pelvic fractures
  - release of a tethered cord
  - repair of coarctation of the aorta
  - resection of fourth ventricular cyst
  - resection of intracranial vascular lesions involving the sensory cortex
  - resection of spinal cord tumor, cyst, or vascular lesion
  - scoliosis correction with instrumentation
  - spinal angiography procedures
  - surgical stabilization of spine fractures with or without spinal cord decompression
  - stereotactic surgery of the brain or brain stem, thalamus, and cerebral cortex
  - thalamus tumor resection / thalamotomy
  - thyroid surgery
- IOM is performed by either a licensed physician trained in clinical neurophysiology (e.g., neurologist, physiatrist) or a trained technologist who is practicing within the scope of his/her license/certification as defined by state law or appropriate authorities and is working under the direct supervision of a physician trained in neurophysiology.
- IOM is interpreted by a licensed physician trained in clinical neurophysiology, other than the operating surgeon, who is either physically in attendance in the operating suite or present by means of a real-time remote mechanism for all electroneurodiagnostic (END) monitoring situations and is immediately available to interpret the recording and advise the surgeon.
- Monitoring is conducted and interpreted real-time (either on-site or at a remote location) and continuously communicated to the surgical team.

**\*Note: IOM for these indications consists of a physician monitoring not more than three cases simultaneously.**

**Cigna does not cover intraoperative monitoring (IOM) of SSEPs for ANY other indication, including during lumbar surgery performed below L1/L2 because it is considered not medically necessary.**

---

## **General Background**

Somatosensory evoked potentials (SSEPs) are noninvasive studies performed by repetitive, submaximal, electrical stimulation of a sensory or mixed sensorimotor peripheral nerve used to aid in the determination of a diagnosis. SSEPs are also used in the intraoperative setting to determine nerve pathway integrity for neurosurgical, orthopedic and vascular procedures that may result in nerve injury. During intraoperative monitoring, needle electrodes are used since they require smaller currents and reduce the stimulus artifact.

The evoked potential response depends on the functional integrity of the nerve that is stimulated. SSEPs in particular are an extension of the electrodiagnostic evaluation and are used to evaluate nerves that cannot be studied by conventional nerve conduction studies, including electromyography. An abnormal SSEP points to a problem in the nerve conduction mechanism that carries the impulse to the brain, however, the SSEP abnormality is not disease specific—an abnormal SSEP indicates impairments associated with certain disorders. An abnormal SSEP signifies an impaired pathway, helps to localize it, and provides a prognostic guide. The SSEP does not provide any indication about the nature of the underlying pathological processes.

Although evoked potentials offer additional information regarding function that can be clinically useful, magnetic resonance imaging (MRI) is often the preferred test to determine structural abnormalities and provides more specific information regarding neurologic structures.

SSEPs are altered by impairment of the somatosensory pathway which may occur as a result of both diffuse (e.g., diseases of myelin, hereditary system degenerations, coma) or local disorders (e.g., tumors, vascular lesions). SSEP abnormalities can be detected in a variety of different settings; therefore, the electrophysiologic findings should be interpreted in the clinical context in which they are obtained (e.g., assessing functional integrity, diagnostic purposes, determining the course of neurological disorders, determining pathological involvement). SSEPs are helpful in evaluating ill-defined complaints. A physician assesses the patient and determines a preliminary differential diagnosis; SSEP testing may then be performed by a trained technologist under the direct supervision of a trained electrodiagnostic physician. Direct supervision implies that a physician is in close proximity to the patient undergoing testing, is immediately available to provide the trained technician with assistance and direction if necessary, and is responsible for determining the SSEP studies that are appropriate.

Evoked potentials are used to assist in diagnosing ill-defined neurological conditions and to categorize afferent pathways that may be responsible for the resulting symptoms experienced by the patient. Conditions for which SSEPs offer clinical utility include (American Association of Neuromuscular and Electrodiagnostic Medicine [AANEM], 2004):

- spinal cord trauma
- subacute combined degeneration
- non traumatic spinal cord lesions (e.g., cervical spondylosis)
- multiple sclerosis
- spinocerebellar degeneration
- myoclonus
- coma

In addition, SSEPs are also useful to evaluate spinal compression associated with syringomyelia and for assessment of hereditary spastic paraplegia (AANEM, 1999).

SSEPs have been utilized to evaluate other peripheral nerve disorders such as acute inflammatory demyelinating polyradiculoneuropathy and focal neuropathies (e.g., entrapment neuropathies, carpal tunnel syndrome, lateral femoral cutaneous neuropathy, medial and lateral plantar neuropathy, saphenous neuropathy, intercostals neuropathy, trigeminal neuropathy, plexopathy) in addition to nerve root dysfunction (i.e., lumbosacral root [acute radiculopathies], thoracic root, cervical root). However, the diagnostic utility of SSEPs for these conditions remains controversial (AANEM, 1999). The AANEM reported that the available evidence is not convincing that SSEPs for these indications provide information that cannot be obtained with conventional nerve conduction studies or needle electromyography.

SSEPs are rarely used to assess peripheral neuropathy as standard nerve conduction velocity studies are the preferred test.

There are no data to suggest a role for SSEPs in the evaluation of behavioral health disorders. The usefulness of evoked potential testing in psychiatry, including SSEPs, is still under investigation (Guse and Love, 2005).

Recordings of SSEP can be normal even in patients with extreme sensory deficits due to the presence of multiple parallel, afferent somatosensory pathways. This procedure is often performed to investigate patients with multiple sclerosis (MS); various coma states, such as those from post-traumatic injury or post-anoxia; suspected brain death; and to indicate the extensiveness of lesion damage in spinal cord injuries. The return or presence of a cortically-generated response to stimulation of a nerve below the injured portion of the cord indicates an incomplete lesion and therefore may offer a better prognosis.

SSEP testing is typically performed bilaterally. Depending on the clinical situation being investigated, several nerves in one extremity may have to be tested and compared with the opposite limb. The physician's SSEP

report should indicate which nerves were tested, latencies at various testing points and an evaluation of whether the results were normal or abnormal.

Sensitivity and specificity reports for electrodiagnostic testing methods (in general) vary. A clearly established measure of comparison is lacking in the medical literature, making comparisons across studies difficult. Some studies have compared results with clinical examination findings, imaging studies such as magnetic resonance imaging, computed tomography, myelography, or the observation of nerve root compression during surgery. Interobserver differences, the variety of tests employed, the presence of symptoms that may influence patient outcomes (e.g., pain), the presence of abnormal imaging studies in asymptomatic patients, and the subjectivity of the surgeon's interpretations may all lead to variances in sensitivity and specificity results. Despite these variances however, electrodiagnostic testing is commonly used to assist in diagnosing disorders involving the nerves, muscles and neuromuscular junction.

### **Intraoperative Monitoring**

Intraoperative monitoring is commonly performed during high-risk complex surgeries where resultant damage to the brain and/r spinal cord may occur. The goal is to improve patient safety by identifying the impairment early so permanent deficits do not result in injuries to the CNS pathways, subsequently improving surgical outcomes.

SSEP is a standard test for intraoperative monitoring; however, motor evoked potentials (MEPs) are also used to monitor motor neurophysiological pathways in addition to electromyography (EMG), also referred to as multimodal intraoperative monitoring (MIOM). SSEP and EMG monitoring combined allows for an intraoperative evaluation that is both sensitive to damage and specific with regards to predicting outcome. SSEPs have low sensitivity to predict damage but high specificity whereas EMG has high sensitivity to nerve root function but low specificity in terms of predicting a persistent neurological deficit (Gunnarsson, et al., 2004).

The AANEM and the AAN published guidance for intraoperative monitoring. According to a position statement by the AANEM (2008) regarding the role of the intraoperative monitoring team, during intraoperative monitoring baseline tracings should be obtained prior to the surgical intervention. Monitoring should continue until closing of the surgical procedure, but may be terminated earlier upon discretion of the surgeon. A logbook should be completed for each patient and include the time of the procedure, the time of each surgical manipulation of the central or peripheral nervous system, and the name, dose and times of anesthetics administered which may affect the central or peripheral nervous system or muscle.

The intraoperative monitoring team should consist of surgeons who have a fundamental background in neurophysiology, a monitoring team with a fundamental background in intraoperative monitoring, and anesthesiologists. In addition, according to the AANEM (2008), the IOM team must include a trained clinical neurophysiologist (MD or DO).

Monitoring must be performed by qualified personnel acting within the scope of his/her license/certification as defined by state law or appropriate authorities. According to a guideline by the AAN (2008), it is expected that a specifically trained technologist or non-physician monitorist, preferably with credentials from the American Board of Neurophysiologic Monitoring or the American Board of Registration of Electrodiagnostic Technologists (ABRET), will be in continuous attendance in the operating room, with either the physical or electronic capacity for real-time communication with the supervising physician. Although credentialing varies among professional organizations, the AANEM and AAN both provide guidance that the monitoring technologist should be under the direct supervision of a clinical neurophysiologist (AAN, 2008; AANEM, 2008).

Typically the physician acts as a remote backup, with the actual intra-operative monitoring being performed in the operating room by a technologist. Some operating rooms have a central physician monitoring room, where a physician may simultaneously monitor cases. The number of procedures being monitored by the clinical neurophysiologist physician is determined by the nature of the surgical procedure. However, according to the AAN (2008) monitoring more than three cases simultaneously is not recommended. The severity of the case being monitored may determine the location of the neurophysiologist; they may be located in the operating room, in the same building, monitoring real-time recordings from a remote location, or at a location from which the operating room is accessible within minutes to view the recording procedure.

When performing intraoperative monitoring, the electroneurodiagnostic technologist should monitor only one surgical procedure at a time; multiple monitoring could result in restricted surgical efficiency, prolonged

anesthesia, and possible compromise of judgment (American Society of Electroneurodiagnostic Technologists' [ASET], 2005).

Real-time monitoring allows for timely intervention to prevent risk of damage. Consequently, it is imperative that either the physical (on-site) or electronic capacity (off-site, remote location) for real-time communication exists between the monitoring team and surgeon.

**Indications:** Despite varying indications in the published literature and from professional societies, there appears to be consensus that determining the need for intraoperative monitoring of SSEPs is dependent upon the complexity of the surgery and the risk of potential damage to neural structures. In general, monitoring of SSEPs is used most often in patients undergoing surgical procedures involving the spinal column and/or spinal cord, and orthopedic, vascular, or other neurological surgery when there is risk of nerve or spinal cord injury. The spinal cord usually ends between L1 and L2. Because of the risk for damage to the spinal cord SSEP (and MEP) may be monitored with spine surgery cephalad to the termination of the cord (Jameson, et al., 2007). In general, surgery where SSEP monitoring has been recommended includes the following (American Society of Neurophysiological Monitoring [ASNM], 2005; Mahla, et al., 2005; Aminoff, 2003; Linden, et al., 1997):

- aortic and thoracic aneurysm repair
- aortic cross-clamping
- arteriovenous malformation of the spinal cord
- brachial plexus surgery/ brachial plexus exploration after injury to the brachial plexus
- brain (e.g., craniotomy for tumor removal, craniotomy for aneurysm repair, carotid endarterectomy, and localization of cortex during craniotomy)
- cerebrovascular surgery
- clipping of intracranial aneurysms
- interventional neuroradiology
- nerve root function (e.g., pedicle screw instrumentation, cauda equina tumor removal, release of tethered cord, spina bifida)
- pelvic fracture surgery
- peripheral nerve and plexus (e.g., peripheral nerve repair, position-related ulnar nerve and brachial plexus dysfunction, avoidance of neuropraxia during shoulder arthroscopy, and protection of sciatic nerve function during hip surgery)
- repair of coarctation of the aorta
- resection of fourth ventricular cyst
- resection of intracranial vascular lesions involving the sensory cortex
- resection of spinal cord tumor, cyst, or vascular lesion
- resection of thalamic tumor
- scoliosis correction with instrumentation
- spinal cord decompression and stabilization after acute spinal cord injury
- spinal cord, including cervical, and thoraco-lumbar (e.g., anterior and posterior cervical spinal fusions, scoliosis/kyphosis correction, abdominal aortic aneurysm, removal of spinal cord tumor, spinal fracture repair, and arteriovenous malformation repair)
- correction of surgical spondylosis
- spine surgery
- stereotactic surgery of the brain stem, thalamus, and cerebral cortex
- surgical correction after spine fractures
- thalamotomy
- thalamus and brain stem (e.g., craniotomy for removal of C-P angle tumor, thalamotomy)
- thyroid surgery

Regarding spine surgery specifically, IOM is indicated in select spine surgeries when there is risk for additional spinal cord injury. Intraoperative monitoring of SSEPs has not been shown to be of clinical benefit for routine lumbar or cervical nerve root decompression (AANEM, 2004), routine lumbar or cervical laminectomy or fusion (AANEM, 1999a). Furthermore, Resnick et al. (2005) reported in guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine that based on the medical literature reviewed by the authors there does not appear to be support for the hypothesis that any form of intraoperative monitoring improves

patient outcomes following lumbar decompression or fusion procedures for degenerative spinal disease. Changes to DSEP and SSEP monitoring appear to be sensitive to nerve root injury, however there is a high false-positive rate; changes are frequently not related to nerve injury. Despite normal SSEPs significant motor deficits have been seen in patients undergoing spinal surgery, consequently MEPs are used to assess motor pathways. MEPS in combination with SSEPs appear to improve the accuracy of spinal cord monitoring (Liem, 2010). Electromyograms are used to monitor nerve root injury during pedicle screw placement and nerve decompressions (Urban, 2009).

**U.S. Food and Drug Administration (FDA):** SSEP devices are evoked stimulator electrical devices used to apply an electrical stimulus through use of skin electrodes, to measure evoked potentials. Several evoked stimulator electrical devices have been approved by the FDA. Evoked response electrical stimulators are regulated by the FDA as Class II devices and are approved through the 510(k) process.

**Summary**

The published scientific literature indicates somatosensory evoked potential (SSEP) studies are useful when used to aid in the diagnosis of various neuromuscular disorders and have varying degrees of sensitivity and specificity. For many conditions, magnetic resonance imaging provides more specific information regarding structural abnormalities and is the preferred test. Evoked potential testing may be clinically useful when diagnostic tests such as MRI do not confirm a diagnosis. Intraoperative monitoring of SSEP is often performed during spinal, orthopedic, vascular, or other neurological surgery when there is risk of nerve root or spinal cord injury, and has been shown to be sensitive in detecting injury to the sensory pathway and adjacent structures. It is the recommendation of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) that electrodiagnostic testing/consultations, including those performed intraoperatively, are conducted by physicians who have a comprehensive knowledge of neurological and neuromusculoskeletal diseases, and in the application of neurophysiologic techniques for evaluation of those disorders.

**Coding/Billing Information**

**Note:** 1) This list of codes may not be all-inclusive.

2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

**Somatosensory Evoked Potentials (SSEPs)**

**Covered when medically necessary:**

<b>CPT®* Codes</b>	<b>Description</b>
95925	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs
95926	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs
95927	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in the trunk or head

<b>ICD-9-CM Diagnosis Codes</b>	<b>Description</b>
192.2	Malignant neoplasm of other and unspecified parts of nervous system, spinal cord
198.3	Secondary malignant neoplasm of brain and spinal cord
225.3	Benign neoplasm of brain and other parts of nervous system, spinal cord
237.5	Neoplasm of uncertain behavior of brain and spinal cord



**EFFECTIVE 2/15/2013**

277.86	Peroxisomal disorders
330.0	Leukodystrophy
333.2	Myoclonus
334.0 – 334.9	Spinocerebellar disease
336.0	Syringomyeloa and syringobulbia
336.2	Subacute combined degeneration of spinal cord in diseases classified elsewhere
336.9	Unspecified disease of spinal cord
340	Multiple sclerosis
341.0 – 341.9	Other demyelinating diseases of central nervous system
344.1	Paraplegia
721.1	Cervical spondylosis with myelopathy
721.41	Thoracic spondylosis with myelopathy
721.42	Lumbar spondylosis with myelopathy
722.71	Intervertebral disc disorder with myelopathy, cervical
723.0	Spinal stenosis in cervical region
724.01	Spinal stenosis in thoracic region
724.03	Spinal stenosis of lumbar region with neurogenic claudication
742.59	Other specified anomalies of spinal cord, other
767.4	Birth trauma, injury to spine and spinal cord
780.01	Alteration of consciousness, coma
806.00 – 806.09	Fracture of vertebral column with spinal cord injury, cervical, closed
806.10-806.19	Fracture of vertebral column with spinal cord injury, cervical, open
806.20 – 806.29	Fracture of vertebral column with spinal cord injury, dorsal (thoracic), closed
806.30-806.39	Fracture of vertebral column with spinal cord injury, dorsal (thoracic), open
806.4	Fracture of vertebral column with spinal cord injury, lumbar closed
806.5	Fracture of vertebral column with spinal cord injury, lumbar, open
952.00-952.9	Spinal cord injury without evidence of spinal bone injury

**Experimental/Investigational/Unproven/Not Covered:**

<b>ICD-9-CM Diagnosis Codes</b>	<b>Description</b>
239.6	Neoplasm of unspecified nature, brain
353.2	Cervical root lesions, not elsewhere classified
353.3	Thoracic root lesions, not elsewhere classified
353.4	Lumbosacral root lesions, not elsewhere classified
433.10	Occlusion and stenosis of carotid artery without mention of cerebral infarction
721.0	Cervical spondylosis without myelopathy
722.10	Lumbar intervertebral disc without myelopathy
722.2	Displacement of intervertebral disc, site unspecified, without myelopathy
722.4	Degeneration of cervical intervertebral disc
722.52	Degeneration of lumbar or lumbosacral intervertebral disc
723.0	Spinal stenosis in cervical region
724.02	Spinal stenosis, other than cervical, lumbar region without neurogenic claudication
729.5	Pain in limb
782.0	Disturbance of skin sensation
953.0	Injury to cervical nerve root
953.2	Injury to lumbar nerve root
953.3	Injury to sacral nerve root
	All other codes

**Intraoperative Monitoring of SSEPs**

**Covered as medically necessary:**

<b>CPT®* Codes</b>	<b>Description</b>
95920	Intraoperative neurophysiology testing, per hour (List separately in addition to code for primary procedure)
95925	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs
95926	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in lower limbs
95927	Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in the trunk or head

<b>ICD-9-CM Diagnosis Codes</b>	<b>Description</b>
170.2	Malignant neoplasm of vertebral column, excluding sacrum and coccyx
191.1	Malignant neoplasm of brain, frontal lobe
192.0-192.9	Malignant neoplasm of other and unspecified parts of nervous system
193	Malignant neoplasm of thyroid gland
198.3	Secondary malignant neoplasm of brain and spinal cord
198.4	Secondary malignant neoplasm of other parts of nervous system
210.2	Benign neoplasm major salivary glands
225.0-225.9	Benign neoplasm of brain and other parts of nervous system
226	Benign neoplasm of thyroid glands
237.4	Neoplasm of uncertain behavior, of endocrine glands and nervous system, other and unspecified
237.70-237.72	Neurofibromatosis disorders
237.9	Neurofibromatosis, other and unspecified parts of nervous system
239.6	Neoplasm of brain
241.0-241.9	Nontoxic nodular goiter
252.00-252.08	Disorders of parathyroid gland; hyperparathyroidism
252.1	Disorders of parathyroid gland; hypoparathyroidism
324.1	Intraspinal abscess
336.0-336.9	Other diseases of spinal cord
343.8	Other specified infantile cerebral palsy
343.9	Infantile cerebral palsy, unspecified
348.4	Compression of brain
350.1-350.2	Trigeminal nerve disorders
352.9	Unspecified disorder of cranial nerves
353.0-353.4	Nerve root and plexus disorders
384.20-384.25	Perforation of tympanic membrane
385.30-385.35	Cholesteatoma of middle ear and mastoid
430	Subarachnoid hemorrhage
431	Intracerebral hemorrhage
432.1	Subdural hemorrhage
432.9	Unspecified intracranial hemorrhage
433.00-433.01	Occlusion and stenosis of basilar artery
433.10-433.11	Occlusion and stenosis of carotid artery
433.20-433.21	Occlusion and stenosis of vertebral artery



**EFFECTIVE 2/15/2013**

433.30-433.31	Occlusion and stenosis of multiple and bilateral precerebral arteries
433.80-433.81	Occlusion and stenosis of other specified precerebral arteries
433.90-433.91	Occlusion and stenosis of unspecified precerebral arteries
434.00-434.01	Cerebral thrombosis
434.10-434.11	Cerebral embolism
434.90-434.91	Cerebral artery occlusion
435.0-435.9	Transient cerebral ischemia
437.3	Cerebral aneurysm, nonruptured
437.5	Moyamoya disease
441.00-441.9	Dissection of aorta
443.21-443.29	Other arterial dissection
721.1	Cervical spondylosis with myelopathy
721.41	Thoracic spondylosis with myelopathy
721.91	Spondylosis of unspecified site, with myelopathy
722.2	Displacement of intervertebral disc, site unspecified, without myelopathy
722.4	Degeneration of cervical intervertebral disc
722.6	Degeneration of intervertebral disc, site unspecified
722.70-722.73	Intervertebral disc disorder with myelopathy
737.10-737.19	Kyphosis (acquired)
737.20-737.22	Lordosis (acquired)
737.30-737.39	Kyphoscoliosis and scoliosis
737.40-737.43	Curvature of spine associated with other conditions
737.8	Other curvatures of spine
738.4	Acquired spondylolisthesis
741.00-741.03	Spina bifida with hydrocephalus
741.90-741.93	Spina bifida without mention of hydrocephalus
747.81	Anomalies of cerebrovascular system
747.82	Spinal vessel anomaly
767.4	Injury to spine and spinal cord
767.5	Facial nerve injury
767.6	Injury to brachial plexus
767.7	Other cranial and peripheral nerve injuries
806.01-806.39	Fracture of vertebral column with spinal cord injury; cervical, thoracic
806.4	Fracture of vertebral column with spinal cord injury, lumbar closed
806.5	Fracture of vertebral column with spinal cord injury, lumbar open
806.70-806.9	Fracture of vertebral column with spinal cord injury; sacrum, coccyx
850.4	Concussion with prolonged loss of consciousness, without return to pre-existing conscious level
953.0-953.9	Injury to nerve roots and spinal plexus

**Not Medically Necessary/Not Covered:**

ICD-9-CM Diagnosis Codes	Description
	All other codes

**\*Current Procedural Terminology (CPT®) © 2012 American Medical Association: Chicago, IL.**

**References**

1. American Academy of Neurology (AAN). Assessment: Dermatomal Somatosensory Evoked Potentials. Reports of the American Academy of Neurology's Therapeutics and Technology Assessments Committee. Approved November 1995. Approved by the AAN Practice Committee December 1995.

Approved by the AAN Executive Board January 1996. Copyright ©1997. Current guideline re-affirmed 10/17/2003. Published: Neurology 1997;49:1127-30.

2. American Academy of Neurology (AAN). Principles of coding for intraoperative neurophysiologic monitoring (IOM) and testing model medical policy. 2008. Updated February 2012. Accessed July 10, 2012. Available at URL address: <http://www.aan.com/globals/axon/assets/9339.pdf>
3. American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Somatosensory evoked potentials. Clinical uses. Chapter 5. Muscle Nerve 22: Supplement 8: S111-S118, 1999a. Accessed July 10, 2012. Available at URL address: <http://www.aanem.org/getmedia/b7bb2cfb-802f-49ff-94c8-1104ef217c61/SEPClinicalUses.pdf.aspx>
4. American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Position Statement. Technologists conducting nerve conduction studies and somatosensory evoked potential studies independently to be reviewed by a physician at a later time. Approved by the American Association of Electrodiagnostic Medicine May 1999b. Copyright ©1995- 2010; by the AANEM. Accessed July 10, 2012. Available at URL address: <http://www.aanem.org/Practice/Position-Statements.aspx>
5. American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). Recommended policy for electrodiagnostic medicine. Endorsed by the American Academy of Neurology, The American Academy of Physical Medicine and Rehabilitation, and The American Association of Neuromuscular and Electrodiagnostic Medicine. Accessed July 10, 2012. Updated 2004. Copyright ©1995-2010; by the AANEM. Available at URL address: <http://www.aanem.org/Practice/Position-Statements.aspx>
6. American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). The Role of the Intraoperative Monitoring Team. AANEM Position Statement. Approved September 16, 2008. Accessed July 10, 2012. Available at URL address: <http://www.aanem.org/Practice/Position-Statements.aspx>
7. American Clinical Neurophysiology Society (ACNS). Standards for short latency somatosensory evoked potentials. August 5, 2004. Accessed July 10, 2012. Available at URL address: <https://www.acns.org/>
8. American Clinical Neurophysiology Society (ACNS). Guidelines for intraoperative monitoring of sensory evoked potentials. August 5, 2004, updated 2006. Accessed July 10, 2012. Available at URL address: <http://www.acns.org/pdfs/ACFDFO.pdf>
9. American Society of Electroneurodiagnostic Technologists (ASET). Simultaneous intraoperative monitoring. Professional Standards and Best Practices. Accessed July 10 2012. Available at URL address: <http://www.aset.org/i4a/pages/index.cfm?pageid=3288>
10. American Society of Neurophysiological Monitoring (ASNM). Intraoperative monitoring using somatosensory evoked potentials. A position statement by the American Society of Neurophysiological Monitoring. J Clin Monit Comput. 2005 Jun;241-58 (18).
11. American Speech-Language-Hearing Association. Neurophysiologic Intraoperative Monitoring. Position Statement. Copyright © 1992 American Language-Speech-Hearing Association. Accessed July 10, 2012. Available at URL address: <http://www.asha.org/docs/html/PS1992-00036.html>
12. Aminoff MJ. Somatosensory evoked potentials. In: Goetz: Textbook of Clinical Neurology, 2<sup>nd</sup> edition. Chapter 24. Electrophysiology. Copyright ©2003 Elsevier. Pages 477-79.
13. Aminoff, MJ, Weiskopf, RB. Electrophysiologic testing for the diagnosis of peripheral nerve injury. Anesthesiology. May 1, 2004;100(5):1298-303.
14. Burke DJ, Hicks RG. Intraoperative monitoring with motor and sensory evoked potentials. In: Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven Publishers. Philadelphia –New York.Ch 22.

15. Burneo, JG. Somatosensory evoked potentials: clinical applications. eMedicine. Updated May 26, 2010. Accessed May 27, 2011. Available at URL address: <http://www.emedicine.com/neuro/topic344.htm>
16. Chawla J, Burneo JG, Barkley GL. Clinical Applications of Somatosensory Evoked Potentials. Medscape. Updated April 2012. Accessed July 10, 2012. Available at URL Address: <http://emedicine.medscape.com/article/1139393-overview#showall>
17. Chiappa K. Electrophysiologic monitoring during carotid endarterectomies. In: Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven Publishers. Philadelphia – New York. Ch. 19.
18. Chiappa K, Cros D. Dermatomal somatosensory evoked potentials. In: Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven Publishers. Philadelphia –New York. Ch. 12.
19. Cruccu G, Aminoff MJ, Curio G, Guerit JM, Kakigi R, Mauguiere F, Rossini PM, Treede RD, Garcia-Larrea L. Recommendations for the clinical use of somatosensory-evoked potentials. Clin Neurophysiol. 2008 May 15.
20. Devlin VJ, Schwartz DM. Intraoperative neurophysiologic monitoring during spinal surgery. J Am Acad Orthop Surg. 2007 Sep;15(9):549-60.
21. Emerson RG, Adams DC, Nagle KJ. Monitoring of spinal cord function intraoperatively using motor and somatosensory evoked potentials. In: Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven Publishers. Philadelphia –New York. Ch 20.
22. Erickson L, Costa V, McGregor M. Intraoperative neurophysiological monitoring during spinal surgery. Montreal: Technology Assessment Unit of the McGill University Health Centre (MUHC), 2005:39.
23. Gunnarsson T, Krassioukov AV, Sarjeant R, Fehlings MG. Real-time continuous intraoperative electromyographic and somatosensory evoked potential recordings in spinal surgery: Correlation of clinical and electrophysiologic findings in a prospective, consecutive series of 213 cases. Spine. 2004;29(6):677-84.
24. Guse BH, Love MJ. Medical assessment and laboratory testing in psychiatry. In: Saydock BJ, Saydock VA, editors. Kaplan and Saydock's Comprehensive Textbook of Psychiatry. 8<sup>th</sup> ed, 2005. p. 919.
25. Jameson LC, Janki DJ, Sloan TB. Electrophysiologic Monitoring in Neurosurgery. Anesthesiol Clin. 2007 Sep; 25(3): 605-30, x
26. Katifi HA, Sedgwick EM. Evaluation of the dermatomal somatosensory evoked potential in the diagnosis of lumbo-sacral root compression. J Neurol Neurosurg Psychiatry. 1987 Sep;50(9):1204-10.
27. Khan MH, Smith PN, Balzer JR, Crammond D, Welch WC, Gerszten P, Sclabassi RJ, Kang JD, Donaldson WF. Intraoperative somatosensory evoked potential monitoring during cervical spine corpectomy surgery: experience with 508 cases. Spine. 2006 Feb 15;31(4):E105-13.
28. Kraft, GH. Dermatomal somatosensory-evoked potentials in the evaluation of lumbosacral spinal stenosis. Phys Med Rehabil Clin N Am. February 2003;14(1):71-5.
29. Liem LK. Intraoperative neurophysiological monitoring. eMedicine specialties. Neurology. Electroencephalography and evoked potentials. Updated Feb 2010 Accessed May 27, 2011. Available at URL address: <http://emedicine.medscape.com/article/1137763-overview>
30. Linden RD, Zappulla R, Shileds CB. Intraoperative evoked potential monitoring. In: Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. ©1997. Lippincott-Raven Publishers. Philadelphia – New York. Ch. 18.

31. Mahla ME, Black S, Cucchiara RF. Intraoperative monitoring of sensory evoked potentials. In: Miller RD, editor. Miller's Anesthesia, 6<sup>th</sup> ed. Ch 38. Neurologic monitoring. Copyright © 2005. Churchill Livingstone.
32. Malhotra NR, Shaffrey CI. Intraoperative electrophysiological monitoring in spine surgery. Spine (Phila Pa 1976). 2010 Dec 1;35(25):2167-79.
33. Nuwer MR, Emerson RG, Galloway G, et al. Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society. Neurology 2012;78;585-589.
34. Resnick DK, Choudhri TF, Dailey AT, Groff MW, Khoo L, Matz PG, Mummaneni P, Watters WC 3<sup>rd</sup>, Wang J, Walters BC, Hadley MN; American Association of Neurological Surgeons/Congress of Neurological Surgeons. Guidelines for the performance of fusion procedures for degenerative disease of the lumbar spine. Part 15: electrophysiological monitoring and lumbar fusion. J Neurosurg Spine. 2005 Jun;2(6):725-32.
35. Snowden ML, Haselkorn JK, Kraft GH, Bronstein AD, Bigos SJ, Slimp JC, Stolov WC. Dermatomal somatosensory evoked potentials in the diagnosis of lumbosacral spinal stenosis: comparison with imaging studies. Muscle Nerve. 1992 Sep;15(9):1036-44.
36. Soliman, E. Somatosensory evoked potentials: General principles. eMedicine. Updated Sep 18, 2010 Accessed May 27, 2011. Available at URL address: <http://www.emedicine.com/neuro/topic640.htm>
37. Storm SA, Kraft GH. The clinical use of dermatomal somatosensory evoked potentials in lumbosacral spinal stenosis. Phys Med Rehabil Clin N Am. 2004 Feb;15(1):107-15.
38. Sutter MA, Eggspuehler A, Grob D, Porchet F, Jeszszky D, Dvorak J. Multimodal intraoperative monitoring (MIOM) during 409 lumbosacral surgical procedures in 409 patients. Eur Spine J. 2007 Nov;16 Suppl 2:S221-8. Epub 2007 Oct 3.
39. Tsai TM, Tsai CL, Lin TS, Lin CC, Jou IM. Value of dermatomal somatosensory evoked potentials in detecting acute nerve root injury: an experimental study with special emphasis on stimulus intensity. Spine. 2005 Sep;30(18):E540-6.
40. Urban MK. Anesthesia for Orthopedic Surgery. In: Miller: Miller's Anesthesia, 7<sup>th</sup> edition. Ch 70. Copyright © 2009 Churchill Livingstone
41. Yiannikas C. Short-latency somatosensory evoked potentials in peripheral nerve lesions, plexopathies, and radiculopathies. In: Chiappa K, editor. Evoked potentials in clinical medicine. Third edition. Lippincott-Raven Publishers © 1997. Philadelphia –New York. Ch. 10.

The registered mark "Cigna" and the "Tree of Life" logo are owned by Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include Connecticut General Life Insurance Company, Cigna Health and Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. In Arizona, HMO plans are offered by Cigna HealthCare of Arizona, Inc. In California, HMO plans are offered by Cigna HealthCare of California, Inc. In Connecticut, HMO plans are offered by Cigna HealthCare of Connecticut, Inc. In North Carolina, HMO plans are offered by Cigna HealthCare of North Carolina, Inc. In Virginia, HMO plans are offered by Cigna HealthCare Mid-Atlantic, Inc. All other medical plans in these states are insured or administered by Connecticut General Life Insurance Company or Cigna Health and Life Insurance Company.